Saul A Rosenberg

Publications

• Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. Advani RH, Hoppe RT, Maeda LS, Baer DM, Mason J, Rosenberg SA, Horning SJ. Int J Radiat Oncol Biol Phys. 2011; 81 (5): 1374-9
• Rare presentation of classical Hodgkin lymphoma with a clonal T-cell receptor gene rearrangement in the tissue. Nguyen TT, Warnke RA, Seo K, Rosenberg SA, Arber DA. Leuk Lymphoma. 2010; 51 (7): 1356-9
• Follicular lymphoma revisited. Rosenberg SA, J Clin Oncol. 2008; 26 (4): 515-6
• Lymphography: a great advance, abandoned. Rosenberg SA, J Clin Oncol. 2008; 26 (35): 5662-3
• Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ. J Clin Oncol. 2007; 25 (25): 3902-7
• Splenic diffuse large B-cell lymphoma in a patient with type 1 Gaucher disease: Diagnostic and therapeutic challenges. Brody JD, Advani R, Shin LK, Bingham DB, Rosenberg SA. Ann Hematol. 2006; 85 (11): 817-20
• Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. Advani R, Rosenberg SA, Horning SJ. J Clin Oncol. 2004; 22 (8): 1454-9
• Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. J Clin Oncol. 2002; 20 (3): 630-7
• High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Horning SJ, Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD, Brown BW, Blume KG. Blood. 2001; 97 (2): 404-9
• Treatment of multicentric Castleman's disease complicated by the development of non-Hodgkin's lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support. Advani R, Warnke R, Rosenberg S. Ann Oncol. 1999; 10 (10): 1207-9
• Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Blood. 1997; 89 (3): 814-22
• Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. Horning SJ, Hoppe RT, Mason J, Brown BW, Hancock SL, Baer D, Rosenberg SA. J Clin Oncol. 1997; 15 (5): 1736-44
• Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. Horning SJ, Rosenberg SA, Hoppe RT. Ann Oncol. 1996: 7 Suppl 4 105-8
• The management of Hodgkin's disease: half a century of change. The Kaplan Memorial Lecture. Rosenberg SA, Ann Oncol. 1996; 7 (6): 555-60
• Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. J Clin Oncol. 1995; 13 (5): 1080-8
• Classification of lymphoid neoplasms. Rosenberg SA, Blood. 1994; 84 (5): 1359-60
• Modern combined modality management of Hodgkin's disease. Rosenberg SA, Curr Opin Oncol. 1994; 6 (5): 470-2
• The treatment of Hodgkin's disease. Rosenberg SA, Ann Oncol. 1994: 5 Suppl 2 17-21
• Reducing the toxicity of the combined modality therapy of favourable stage Hodgkin's disease. Rosenberg SA, Eur J Cancer. 1992; 28A (8-9): 1379-80
• The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease. Horning SJ, Ang PT, Hoppe RT, Rosenberg SA. Ann Oncol. 1992; 3 (9): 747-54
• The continuing challenge of Hodgkin's disease. Rosenberg SA, Ann Oncol. 1991: 2 Suppl 2 29-31
• CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Chao NJ, Rosenberg SA, Horning SJ. Blood. 1990; 76 (7): 1293-8
• Current Stanford clinical trials for Hodgkin's disease. Hoppe RT, Horning SJ, Hancock SL, Rosenberg SA. Recent Results Cancer Res. 1989: 117 182-90
• Hodgkin's disease: challenges for the future. Rosenberg SA, Cancer Res. 1989; 49 (4): 767-9
• Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. Leibenhaut MH, Hoppe RT, Efron B, Halpern J, Nelsen T, Rosenberg SA. J Clin Oncol. 1989; 7 (1): 81-91
• Exploratory laparotomy and splenectomy for Hodgkin's disease: a commentary. Rosenberg SA, J Clin Oncol. 1988; 6 (4): 574-5
• Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. Hancock SL, Hoppe RT, Horning SJ, Rosenberg SA. Ann Intern Med. 1988; 109 (3): 183-9
• Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. Horning SJ, Hoppe RT, Hancock SL, Rosenberg SA. J Clin Oncol. 1988; 6 (12): 1822-31